Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIQ

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIQ - Post by User

IMV Inc > Presentations
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by Breakthoroughon Apr 08, 2022 2:06pm
334 Views
Post# 34588644

RE:RE:RE:RE:Presentations

RE:RE:RE:RE:Presentations ORR: 29'4% (CR 11'8%, PR: 17'6%) mOS (Overall Survival): not reached. But "long-term clinical benefit has been observed in several subjects (one patient is still on treatment after 17 months)" Keytruda was approved for this population in may 2017 with: ORR of 21% (better than the 11% of quimio). NO CR's, I guess. mOS: 10'3 months (better than the 7'4 months of quimio). All this in patients who had received Keytruda before this trial (76'4 of them, includind the ones that now reached CR).
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities